Skip to main content
SpringerLink
Log in

Nonsteroidal Antiandrogens

  • Chapter
Hormone Therapy in Breast and Prostate Cancer

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Antiandrogens offer treatment options for patients with early and advanced prostate cancer, either as a single agent or as part of a combination with surgical or medical castration. They are most frequently used as a component of combined androgen blockade (CAB) in locally advanced or metastatic disease. The antiandrogens are classified by their chemical structure as either steroidal compounds, typified by cyproterone acetate, or nonsteroidal compounds, which are discussed here. Three nonsteroidal antiandrogens (NSAAs) are currently available: flutamide, nilutamide, and bicalutamide (Fig. 1). Flutamide has been in clinical use for more than 20 years. It is a pro-drug and is converted in the liver to the active metabolite 2-hydroxyflutamide (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Katchen B, Buxbaum S. Disposition of a new, nonsteroid, antiandrogen,α,α,α-trifluoro-2-methyl-4-nitro-m-propionotoluidide (flutamide), in men following a single oral 200 mg dose. J Clin Endocrinol Metab 1975; 41:373–379.

    Article  PubMed  CAS  Google Scholar 

  2. Mukherjee A, Kirkovsky L, Yao XT, Yates RC, Miller DD, Dalton JT. Enantioselective binding of Casodex to the androgen receptor. Xenobiotica 1996; 26:117–122.

    Article  PubMed  CAS  Google Scholar 

  3. Huggins C, Stevens RE, Hodges CV. Studies in prostatic cancer, II. The effects of castration on advanced cancer of the prostate gland. Arch Surg 1941; 43:209–223.

    CAS  Google Scholar 

  4. Ayub M, Levell MJ. The effect of ketoconazole related imidazole drugs and antiandrogens on [3H]R1881 binding to the prostatic androgen receptor and [3H]5α-dihydrotestosterone and [3H]cortisol binding to plasma proteins. J Steroid Biochem 1989; 33:251–255.

    Article  PubMed  CAS  Google Scholar 

  5. Gaillard-Moguilewsky M. Pharmacology and antiandrogens and value of combining androgen suppression with antiandrogen therapy. Urology 1991; 37(Suppl):5–12.

    Article  PubMed  CAS  Google Scholar 

  6. Furr BJA, Tucker H. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 1996; 47(Suppl 1A):13–25.

    Article  PubMed  CAS  Google Scholar 

  7. Furr BJA, Valcaccia B, Curry B, Woodburn JR, Chesterson G, Tucker H. ICI 176, 334: a novel non-steroidal, peripherally selective antiandrogen. J Endocrinol 1987; 113:R7–R9.

    Article  PubMed  CAS  Google Scholar 

  8. Freeman SN, Mainwaring WIP, Furr BJA. A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334). Br J Cancer 1989; 60:664–668.

    PubMed  CAS  Google Scholar 

  9. Marchetti B, Labrie F. Characteristics of flutamide action on prostatic and testicular functions in the rat. J Steroid Biochem 1988; 29:691–698.

    Article  PubMed  CAS  Google Scholar 

  10. Mahler C, Van Cangh P, Bouffioux C, Keuppens F, Coeck C, Ongena P, Denis L. Endocrine effects of Casodex. A new non-steroidal antiandrogen, in Recent Advances in Urological Cancers (Murphy G, Khoury S, eds). American Cancer Society, Atlanta, GA 1990:42–45.

    Google Scholar 

  11. Moguileswky M, Fiet J, Tournemine C, Raynaud JP. Pharmacology of an antiandrogen, anandron, used as adjuvant therapy in the treatment of prostate cancer. J Steroid Biochem 1986; 24:139–146.

    Article  Google Scholar 

  12. Teutsch G, Goubet F, Baumann J, Bonfils A, Bouchoux F, Cerede E, et al. Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J Steroid Biochem 1994; 48:111–119.

    Article  CAS  Google Scholar 

  13. Winneker REC, Wagner MM, Batzold FH. Studies on the mechanism of action of WIN49596: a steroidal androgen receptor antagonist. J Steroid Biochem 1989; 33:1133–1138.

    Article  PubMed  CAS  Google Scholar 

  14. Luo S, Martel C, LeBlanc G, Candas B, Singh SM, Labrie C, Simard J, Belanger A, Labrie F. Relative potencies of flutamide and Casodex: preclinical studies. Endocr-Rel Cancer 1996; 3:229–241.

    Article  CAS  Google Scholar 

  15. Kemppainen JA, Wilson EM. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilisation. Urology 1996; 48:157–163.

    Article  PubMed  CAS  Google Scholar 

  16. Furr BJA. Relative potencies of flutamide and Casodex. Endocr-Rel Cancer 1997; 4:197–202.

    Article  CAS  Google Scholar 

  17. Kolvenbag GJCM, Furr BJA, Blackledge GRP. Receptor affinity and potency of nonsteroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostat Dis 1998; 1:307–314.

    Article  CAS  Google Scholar 

  18. Snyder BW, Winneker RC, Batzold FH. Endocrine profile of WIN 49596 in the rat: a novel androgen receptor antagonist. J Steroid Biochem 1989; 33:1127–1132.

    Article  PubMed  CAS  Google Scholar 

  19. Chandolia RK, Weinbauer GF, Behre HM, Nieschlag E. Evaluation of a peripherally selective antiandrogen (Casodex) as a tool for studying the relationship between testosterone and spermatogenesis in the rat. J Steroid Biochem Mol Biol 1991; 38:367–375.

    Article  PubMed  CAS  Google Scholar 

  20. Chandolia RK, Weinbauer GF, Simoni M, Behre HM, Nieschlag E. Comparative effects of chronic administration of the non-steroidal antiandrogens flutamide and Casodex on the reproductive system of the adult male rat. Acta Endocrinol 1991; 125:547–555.

    PubMed  CAS  Google Scholar 

  21. Gromoll J, Weinbauer GF, Simoni M, Nieschlag E. Effects of antiandrogens and ethane dimethane sulphonate (EDS) on gene expression, free subunits, bioactivity and secretion of pituitary gonadotrophins in male rats. Mol Cell Endocrinol 1993; 91:119–125.

    Google Scholar 

  22. Darbre PD, King RJB. Progression to steroid autonomy in S115 mouse mammary tumor cells: role of DNA methylation. J Cell Biol 1984; 99:1410–1415.

    Article  PubMed  CAS  Google Scholar 

  23. Maucher A, von Angerer E. Antiproliferative activity of Casodex (ICI 176,334) in hormone-dependent tumors. J Cancer Res Clin Oncol 1993; 119:669–674.

    Article  PubMed  CAS  Google Scholar 

  24. Simard J, Singh SM, Labrie F. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. Urology 1997; 49:580–589.

    Article  PubMed  CAS  Google Scholar 

  25. Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989; 14:103–115.

    Article  PubMed  CAS  Google Scholar 

  26. Olea N, Sakabe K, Soto AM, Sonnenschein C. The proliferative effect of antiandrogens on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology 1990; 126:1457–1463.

    Article  PubMed  CAS  Google Scholar 

  27. Schuurmans ALG, Bolt J, Veldscholte J, Mulder E. Simulatory effects of antiandrogens on LNCaP human prostate tumor cell growth. EGF-receptor level and acid phosphatase secretion. J Steroid Biochem Mol Biol 1990; 37:849–853.

    Article  PubMed  CAS  Google Scholar 

  28. Veldscholte J, Berevoets CA, Brinkman AO, Grootegoed JA, Mulder E. Antiandrogens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heatshock protein interaction, and transcription activation. Biochemistry 1992; 31:2392–2399.

    Google Scholar 

  29. Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Bartsch G, Klocker H. Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy. Drugs Aging 1997; 10:50–58.

    Article  PubMed  CAS  Google Scholar 

  30. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997; 3:1383–1388.

    PubMed  CAS  Google Scholar 

  31. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, et al. High-dose bicalutamide for androgen-independent prostate cancer. J Urol 1998; 159:149–153.

    Article  PubMed  CAS  Google Scholar 

  32. Furr BJA. Casodex: preclinical studies. Eur Urol 1990; 18:2–9.

    PubMed  Google Scholar 

  33. Aso Y, Akaza H, Kameyama S, Koyanagi T, Kumamoto Y, Funyu T. Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer. Phase II dose-finding study. Acta Urol Jpn 1993; 39:391–403.

    CAS  Google Scholar 

  34. Denis L, Mahler C. Pharmacodynamics and pharmacokinetics of bicalutamide: defining an active dosing regimen. Urology 1996; 47(suppl 1A):26–28.

    Article  PubMed  CAS  Google Scholar 

  35. Blackledge GRP, Cockshott JD, Furr BJA. Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. Eur Urol 1997; 31(Suppl 2):30–39.

    PubMed  CAS  Google Scholar 

  36. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 1995; 45:745–752.

    Article  PubMed  CAS  Google Scholar 

  37. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996; 47:38–43.

    Article  PubMed  CAS  Google Scholar 

  38. Schulz M, Schmeldt A, Donn F, Becker H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J Clin Pharmacol 1988; 34:633–636.

    Article  PubMed  CAS  Google Scholar 

  39. Pendyala L, Creaven PJ, Huben R, Tremblay D, Bertagna C. Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate. Cancer Chemo Pharmacol 1988; 22:69–76.

    CAS  Google Scholar 

  40. Cockshott ID, Cooper KJ, Sweetmore DS, Blacklock NJ, Denis L. The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol 1990; 18 (Suppl 3):10–17.

    PubMed  Google Scholar 

  41. McKillop D, Boyle GW, Cockshott ID, Jones DC, Phillips PJ, Yates RA. Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica 1993; 23:1241–1253.

    Article  PubMed  CAS  Google Scholar 

  42. Kirby RS. Recent advances in the medical management of prostate cancer. Br J Clin Pract 1996; 50:88–93.

    PubMed  CAS  Google Scholar 

  43. Bracci U, DiSilverio F. Role of cyproterone acetate in urology, in Androgens and Antiandrogens (Martini L, Motta M, eds). Raven Press, New York, 1977, pp 333–339.

    Google Scholar 

  44. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419–424.

    PubMed  CAS  Google Scholar 

  45. Denis LJ, de Moura CJL, Bono A, Sylvester R, Whelan P, Newling D, Depauw M. Goserelin acetate and flutamide versus bilateral orchidectomy: a phase III EORTC trial (30853). Urology 1993; 42:119–130.

    Article  PubMed  CAS  Google Scholar 

  46. Dijkman GA, Janknegt RA, de Reijke TM, Debrunye FMJ. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol 1997; 158:160–163.

    Article  PubMed  CAS  Google Scholar 

  47. Eisenberger M, Crawford ED, McLeod D, Loehrer P, Wilding G, Blumenstein B. A comparison of bilateral orchidectomy with or without flutamide in stage D2 prostate cancer (NCI INT-0105 SWOG/ECOG). Proc Am Soc Clin Oncol 1997; 16:2a (Abstr 3).

    Google Scholar 

  48. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346:265–269.

    Google Scholar 

  49. Klotz LH, Newman T. Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence. Can J Urol 1996; 3:246–250.

    PubMed  Google Scholar 

  50. Debruyne FM. Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument for. Eur Urol 1996; 29 (suppl 2):34–36.

    PubMed  Google Scholar 

  51. Caubet J-F, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized clinical trials using nonsteroidal antiandrogens. Urology 1997; 49:71–78.

    Article  PubMed  CAS  Google Scholar 

  52. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of randomised trials. Lancet 2000; 355:1491–1498.

    Google Scholar 

  53. Labrie F, Dupont A, Cusan L, Gomez J-L, Diamond P. Major advantages of early administration of endocrine combination therapy in advanced prostate cancer. Clin Invest Med 1993; 16:493–498

    PubMed  CAS  Google Scholar 

  54. Jörgensen T, Muller C, Kaalhus O, Danielson HE, Tveter KJ. Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Eur Urol 1995; 28:40–46.

    PubMed  Google Scholar 

  55. Sarosdy MF, Schellhammer PF, Johnson R, Carroll K, Kolvenbag GJCM. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? Urology 2000; 55:391–396.

    Article  PubMed  CAS  Google Scholar 

  56. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, et al. Clinical benefits of bicalutamide (Casodex) versus flutamide (Eulexin) in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind randomized, multicenter trial. Urology 1997; 50:330–336.

    Google Scholar 

  57. Soloway M, Schellhammer P, Sharifi R, Block N, Venner P, Patterson AL, et al. Differences between bicalutamide and flutamide, each in combination with LHRH analogs, in advanced prostate cancer patients: an exploratory analysis of extent of disease. Prostate J 2000; in press.

    Google Scholar 

  58. Scher HI, Kelly WK. The flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostatic cancer. J Clin Oncol 1993; 11:1566–1572.

    PubMed  CAS  Google Scholar 

  59. Dupont A, Gomez J, Cusan L, Koutsilieris M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993; 150:908–913.

    PubMed  CAS  Google Scholar 

  60. Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of hormone-refractory prostate cancer. J Natl Cancer Inst 1994; 86:222–227.

    Article  PubMed  CAS  Google Scholar 

  61. Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, et al. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 1995; 98:412–414.

    Article  PubMed  CAS  Google Scholar 

  62. Herrada J, Hossan B, Amato R, Zukiwski A, von Esenbach A, Logothetis C. Characterization of patients with androgen independent prostate carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J Urol 1996; 155:620–623.

    Article  PubMed  CAS  Google Scholar 

  63. Small EJ, Carroll PR. Prostate-specific antigen decline after Casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43:408–410.

    Article  PubMed  CAS  Google Scholar 

  64. Nieh PT. Withdrawal phenomenon with the antiandrogen Casodex. J Urol 1995; 153:1070–1073.

    Article  PubMed  CAS  Google Scholar 

  65. Huan SD, Gerridzen RG, Yau JC, Stewart DJ. Antiandrogen withdrawal syndrome with nilutamide. Urology 1997; 49:632–634.

    Article  PubMed  CAS  Google Scholar 

  66. Schellhammer P, Venner P, Haas G, Small EJ, Neih P, Seabaugh DR, et al. Prostate-specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997; 157:1731–1735.

    Article  PubMed  CAS  Google Scholar 

  67. Decensi AU, Boccardo F, Guarneri D, Positano N, Paoletti C, Costantini M, et al. Monotherapy with nilutamide: a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 1991; 146:377–381.

    PubMed  CAS  Google Scholar 

  68. Jacobo E, Schmidt JD, Weinstein SH, Flocks RH. Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer. Urology 1976; 8:231–233.

    Article  PubMed  CAS  Google Scholar 

  69. Sogani PC, Vagaiwala MR, Whitmore WF. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 1984; 54:744–750.

    Article  PubMed  CAS  Google Scholar 

  70. Narayana AS, Loening SA, Culp DA. Flutamide in the treatment of metastatic carcinoma of the prostate. Br J Urol 1981; 53:152–153.

    Article  PubMed  CAS  Google Scholar 

  71. Keating MA, Griffin PP, Schiff SF. Flutamide in the treatment of advanced prostate cancer. J Urol 1986; 135:203a (Abstr 398).

    Google Scholar 

  72. Di Silverio F, Tenaglia R, Bizzarri M, Biggio A, Saragnano R. Experience with flutamide in advanced prostatic cancer patients refractory to previous endocrine therapy. J Drug Dev 1987; 1 (suppl 1):10–16.

    Google Scholar 

  73. Lundgren R. Flutamide as primary treatment for metastatic prostatic cancer. Br J Urol 1987; 59:156–158.

    Article  PubMed  CAS  Google Scholar 

  74. Prout GR, Keating MA, Griffin PP, Schiff SF. Long term experience with flutamide in patients with prostatic carcinoma. Urology 1989; 34:37–45.

    Article  PubMed  Google Scholar 

  75. Pavone-Macaluso M, Pavone C, Serretta Y, Daricello G. Antiandrogens alone or in combination for treatment of prostate cancer: the European experience. Urology 1989; 34:27–35.

    Article  PubMed  CAS  Google Scholar 

  76. Delaere KPJ, Van Thillo EL. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Urol 1991; 18:13–18.

    CAS  Google Scholar 

  77. Johansson JE, Andersson SO, Beckman KW, Lingardh G, Zador G. Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate. Urology 1987; 24:55–59.

    Article  Google Scholar 

  78. Lund F, Rasmussen F. Flutamide versus stilboestrol in the management of advanced prostatic cancer. Br J Urol 1988; 61:140–142.

    Article  PubMed  CAS  Google Scholar 

  79. Pavone-Macaluso M. Flutamide monotherapy versus combined androgen blockade in advanced prostate cancer. Interim report of an Italian multicenter, randomised study. SIU 23rd Congress, Sydney, Australia, September 1994 (Abstr 354).

    Google Scholar 

  80. Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, et al. Double blind randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996; 14:2250–2257.

    PubMed  CAS  Google Scholar 

  81. Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, et al. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997; 32:391–396.

    PubMed  CAS  Google Scholar 

  82. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, et al. A randomised comparison of Casodex (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33:447–456.

    Article  PubMed  CAS  Google Scholar 

  83. Iversen P, Tyrrell CJ, Anderson JB, Baert L, Chamberlain M, Kaisary AV, et al. Comparison of Casodex (bicalutamide) 150 mg monotherapy with castration in previously untreated nonmetastatic prostate cancer: mature survival results. J Urol 2000; 163 (Suppl):158 (Abs 704).

    Article  Google Scholar 

  84. Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani, Comeri G, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian prostate cancer project study. J Clin Oncol 1999; 17:2027–2038.

    PubMed  CAS  Google Scholar 

  85. Chatelain C, Fourcader RO, Delchambre J. Bicalutamide (Casodex) versus combined androgen blockade (CAB): open French multicentre trial in patients with metastatic prostate cancer. Br J Urol 1997; 80 (Suppl 2):283 (Abstr 1111).

    Google Scholar 

  86. Kaisary AV, Tyrrell CJ, Beacock C, Lunglmayr G, Debruyne FA. Randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Eur Urol 1995; 28:215–222.

    PubMed  CAS  Google Scholar 

  87. Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT. Single agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 1995; 46:849–855.

    Article  PubMed  CAS  Google Scholar 

  88. Iversen P, Tveter K, Varenhorst E. Randomised study of Casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. Scand J Urol Nephrol 1996; 30:93–98.

    Article  PubMed  CAS  Google Scholar 

  89. Oosterlinck W, Casselman J, Mattelaer J, van Velthoven R, Kurjatkin O, Schulman C. Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients. Eur Urol 1996; 30:458–463.

    PubMed  CAS  Google Scholar 

  90. Boccardo F, Decensi A, Guarneri D, Rubagotti A, Oneto F, Martorana G, et al. Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an outgoing PONCAP study. Eur Urol 1990; 18(Suppl 3):48–53.

    PubMed  Google Scholar 

  91. Tyrrell CJ, Altwein JE, Klippel F, Varenhorst E, Lunglmayr G, Boccardo F, et al. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J Urol 1991; 146:1321–1326.

    PubMed  CAS  Google Scholar 

  92. Chatelain C, Rousseau V, Cosaert J. French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report. Eur Urol 1994; 26 (Supp 1):10–14.

    Google Scholar 

  93. Namer M, Toubol J, Caty A, Couette JE, Douchez J, Kerbrat P, Droz JP. A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer. J Steroid Biochem Mol Biol 1990; 37:909–915.

    Article  PubMed  CAS  Google Scholar 

  94. Boccardo F, Decensi AU, Guarneri D, Martorana G, Fioretto L, Mini E, et al. Anandron (RU23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study. Cancer Detect Prev 1991; 15:501–503.

    PubMed  CAS  Google Scholar 

  95. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149:77–83.

    PubMed  CAS  Google Scholar 

  96. Boccardo F, Pace M, Rubagotti A, Guarneri D, Decensi A, Oneto F, et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. Eur J Cancer 1993; 29A:1088–1093.

    Article  PubMed  CAS  Google Scholar 

  97. Iversen P, Rasmussen F, Klarskov P, Christensen IJ. Long-term results of Danish Prostatic Cancer Group Trial 86. Cancer 1993; 72(Suppl):3851–3854.

    Article  PubMed  CAS  Google Scholar 

  98. Rosenthal SA, Linstadt DE, Leibenhaut MH, Andras EJ, Brooks CP, Stickney DR, et al. Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Radiology 1996; 199:451–455.

    PubMed  CAS  Google Scholar 

  99. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996; 155:209–212.

    Article  PubMed  CAS  Google Scholar 

  100. Pescatore P, Hammel P, Durand F, Bertheau P, Bernuau J, Huc D, et al. Hepatite fulminante mortelle imputable au nilutamide (Anandron). Gastroenterol Clin Biol 1993; 17:499–501.

    PubMed  CAS  Google Scholar 

  101. Dawson LA, Chow E, Morton G. Fulminant hepatic failure associated with bicalutamide. Urology 1997; 49:283–284.

    Article  PubMed  CAS  Google Scholar 

  102. Schellhammer PF. Fulminant hepatic failure associated with bicalutamide. Urology 1997; 50:827.

    Article  PubMed  CAS  Google Scholar 

  103. Pfizenmeyer P, Foucher P, Piard F, Coudert B, Braud ML, Gabez P, et al. Nilutamide pneumonitis: a report on 8 patients. Thorax 1992; 47:622–627.

    Google Scholar 

  104. Gomez J-L, Dupont A, Cuan L, Tremblay M, Tremblay M, Labrie F. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report. Am J Med 1992; 92:563–566.

    Google Scholar 

  105. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15:2928–2938.

    PubMed  CAS  Google Scholar 

  106. Harnois C, Malenfant M, Dupont A, Labrie F. Ocular toxicity of Anandron in patients treated for prostatic cancer. Br J Ophthalmol 1986; 70:471–473.

    Article  PubMed  CAS  Google Scholar 

  107. Brisset JM, Bertagna C, Fiet J, de Gry A, Hucher M, Husson JM, et al. Total androgen blockade vs orchiectomy in stage D prostate cancer, in Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti) Steroidal Agents (Klijn JGM, ed). Raven Press, New York, 1987, pp 19–30.

    Google Scholar 

  108. Beland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewari HD. Total androgen ablation: Canadian experience. Urol Clin North Am 1991; 18:75–82.

    PubMed  CAS  Google Scholar 

  109. Crawford ED, Smith JA, Soloway MS, Lange PH, Lynch DF, Al-Juburi A, et al. Treatment of stage D2 prostate cancer with leuprolide and Anandron compared to leuprolide and placebo, in Proceedings of the 3rd International Symposium on Recent Advance in Urological Cancers: Diagnosis and Treatment (Murphy G, Khoury S, Chatelain C, Denis L, eds). Paris, SCI 1993, pp 61–63.

    Google Scholar 

  110. Fair WR, Cookson MS, Stroumbakis N, Cohen D, Aprikian AG, Wang Y, et al. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997; 49(Suppl 3A):46–55.

    Article  PubMed  CAS  Google Scholar 

  111. Soloway MS, Shairifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 1995; 154:424–428.

    Article  PubMed  CAS  Google Scholar 

  112. Soloway MS, Shairifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A. Radical prostectomy alone vs radical prostatectomy preceded by androgen blockade in cT2b prostate cancer – 24 month results. Br J Urol 1997; 80(suppl 2):259(Abs 1015).

    Google Scholar 

  113. Cookson MS, Sogani PC, Russo P, Sheinfeld J, Herr H, Dalbagni G, et al. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol 1997; 79:432–438.

    PubMed  CAS  Google Scholar 

  114. Schulman CC, Debruyne FMJ, Forster G, van Cangh PJ, Witjes WPJ. Neoadjuvant combined androgen deprivation therapy in locally confined prostatic carcinoma. Three years of follow up of a European multicentric randomised study. Br J Urol 1997; 80(Suppl 2):259(Abs 1015).

    Google Scholar 

  115. Witjes WPJ, Schulman CC, Debruyne FMJ. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2–3N0 M0 prostatic carcinoma. Urology 1997; 49(Suppl 3A):65–69.

    Article  PubMed  CAS  Google Scholar 

  116. Labrie F, Cusan L, Gomez J-L. Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 1994; 44:29–37.

    Article  Google Scholar 

  117. Labrie F, Cusan L, Gomez J-L, Diamond P, Suburu R, Lemay M, et al. Neoadjuvant hormonal therapy: the Canadian experience. Urology 1997; 49(Suppl 3A):56–64.

    Article  PubMed  CAS  Google Scholar 

  118. Vaillancourt L, Tetu B, Fradet Y, Dupont A, Gomez J, Cusan L, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. Am J Surg Pathol 1996; 20:86–93.

    Article  Google Scholar 

  119. Gleave M, Goldenberg SL, Jones E, Bruchovsky N, Sullivan L. Biochemical and pathological effects of 8 months of neoadjuvant hormonal therapy: an update on 125 consecutive patients. Br J Urol 1997; 80(Suppl 2):259(Abstr 1016).

    Google Scholar 

  120. Pilepich MV, Krall JM, Al-Sarraf M, John MJ, Scotte Doggett RL, Sause WT, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45:616–623.

    Article  PubMed  CAS  Google Scholar 

  121. Candas B, Gomes JL, Cusan L, Diamond P, Laverdiere J, Labrie F. Effects of neoadjuvant and adjuvant combined androgen blockade associated to radiation therapy on serum PSA. Br J Urol 1997; 80(Suppl 2):259 (Abstr 1017).

    Google Scholar 

  122. Laverdiere J, Gomez JL, Cusan L, Suburu ER, Diamond P, Lemay M, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Intl J Radiat Oncol Biol Phys 1997; 37:247–252.

    Article  CAS  Google Scholar 

  123. Zelefsky MJ, Harrison A. neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 1997; 49(Suppl 3A):38–45.

    Article  PubMed  CAS  Google Scholar 

  124. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992; 339:1–14.

    Google Scholar 

  125. Wirth M, Frohmuller H, Marz F, Bolten M, Thieb M. Randomized multicenter trial on adjuvant flutamide therapy in locally advanced prostate cancer after radical surgery. Br J Urol 1997; 80(Suppl 2):263 (Abstr 1033).

    Google Scholar 

  126. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer 1993; 71:2782–2790.

    Article  PubMed  CAS  Google Scholar 

  127. Tunn UW. Intermittent endocrine therapy of prostate cancer. Eur Urol 1996; 30(suppl 1):22–25.

    PubMed  Google Scholar 

  128. Goldenberg S1, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995; 45:839–844.

    Google Scholar 

  129. Gleave M, Bruchovsky N, Goldenberg SL, Sullivan LD. Intermittent androgen suppression: rationale and clinical experience, in Recent Advances in Prostate Cancer and BPH. Proceedings of the 4th Congress on Progress and Controversies in Oncological Urology (PACIOU IV, Rotterdam, April 1996) (Schroeder FH, ed). 1997; 109–120.

    Google Scholar 

  130. Tunn UW. Clinical results of intermittent endocrine treatment in low-volume prostate cancer patients, in Recent Advances in Prostate Cancer and BPH. Proceedings of the 4th Congress on Progress and Controversies in Oncological Urology (PACIOU IV, Rotterdam, April 1996) (Schroeder FH, ed). 1997, pp 121–125.

    Google Scholar 

  131. Pummer K, Lehnert M, Stettner H, Hubmer G. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997; 32(Suppl 3):81–85.

    PubMed  CAS  Google Scholar 

  132. Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol 1995; 154:1642–1646.

    Article  PubMed  CAS  Google Scholar 

  133. Fleshner NE, Fair WR. Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol 1996; 78:907–910.

    PubMed  CAS  Google Scholar 

  134. Ornstein DK, Ran GS, Johnson B, Charlton ET, Andriole CL. Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 1996; 46:901–905.

    Article  Google Scholar 

  135. Brufsky A, Fontaine-Rothe P, Berlane K, Rieker P, Jiroutek M, Kaplan I, et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 1997; 49:913–920.

    Article  PubMed  CAS  Google Scholar 

  136. Sklar GN, Eddy HA, Jacobs SC, Kyprianou N. Combined antitumour effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. J Urol 1993; 150:1520–1532.

    Google Scholar 

  137. Dawson NA, Figg WD, Cooper MR, Sartor O, Bergan RC, Senderowicz AM, et al. Phase II trial of suramin, leuprolide and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 1997; 15:1470–1477.

    PubMed  CAS  Google Scholar 

  138. MacFarlane JR, Tolley DA. Flutamide therapy for advanced prostatic cancer: a phase II study. Br J Urol 1985; 57:172–174.

    Article  PubMed  CAS  Google Scholar 

  139. Kucuk O, Blumenstein B, Moinpour C, Lew D, Coleman M, Eisenberger M, Crawford D. Phase II trial of Casodex in advanced prostate cancer (CaP) patients who failed conventional hormonal manipulation: a Southwest Oncology Group (SWOG) Study. Proc Am Soc Clin Oncol 1996; 15:245 (Abstr 618).

    Google Scholar 

  140. Datta SN, Thomas K, Matthews PN. Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate? J Urol 1997; 158:175–177.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AstraZeneca Pharmaceuticals, Wilmington, DE

    Geert J. C. M. Kolvenbag

  2. AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire, UK

    Barrington J.A. Furr

Authors
  1. Geert J. C. M. Kolvenbag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barrington J.A. Furr
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Rd. NW Research Bldg. E501, Washington, DC, 20057, USA

    V. Craig Jordan

  2. AstraZeneca Pharmaceuticals Zeneca Pharmaceutical, Alderly Park, Alderly House, Macclesfield, SK 10 4TF, UK

    Barrington J.A. Furr

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kolvenbag, G.J.C.M., Furr, B.J. (2009). Nonsteroidal Antiandrogens. In: Jordan, V.C., Furr, B.J. (eds) Hormone Therapy in Breast and Prostate Cancer. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59259-152-7_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-152-7_16

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-471-5

  • Online ISBN: 978-1-59259-152-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation